Oric Pharmaceuticals

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination development

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT.

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

ORIC Pharma's stock has nearly doubled after positive data from its second candidate, ORIC-114, which has shown a best-in-class profile. ORIC-114 has demonstrated minimal toxicity, CNS activity, and systemic activity in patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer. The drug has the potential to address the unmet need for effective CNS accessing medicines in NSCLC patients with brain metastases.

ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting

Ardelyx

Exact Sciences

In the rapidly evolving healthcare sector, the idea of personalized medicine stocks stands out, revolutionizing patient care by tailoring treatments with their individual genetic profiles. These stocks highlight the trend of focusing on genetic and molecular characteristics, promising more effective healthcare solutions.

3 Stocks at the Forefront of Personalized Medicine Trend

Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, CA.

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancers Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancers

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

Oric Pharmaceuticals, Inc. (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 8:00 a.m. ET.

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October 20-24, 2023

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Carnival

Cronos Group

iShares MSCI Emerging Markets ETF

Edwards Lifesciences

Kopin

Principal Financial Group

Prudential Financial

SPDR S&P 500 ETF Trust

Viatris

The stock market, as measured by the S&P 500 Index SPX, -0.64% ), has been moving upward. The U.S. benchmark index is essentially crawling up the higher “modified Bollinger Bands” (mBB), which is a bit of an overbought condition, but not a sell signal.

You can still run with the stock market's bulls, but watch the exits

Oric Pharmaceuticals specializes in oncology therapies. The company said the private placement will help it fund operations through the end of 2025.

Why Shares of Oric Pharmaceuticals Jumped Monday

Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital

ORIC Pharmaceuticals Announces $85 Million Private Placement Financing

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 10:00 a.m. ET.

ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023:  ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

Avalo Therapeutics

Twist Bioscience Corp

INmune Bio Inc

Synlogic

Tenaya Therapeutic

Personalized medicine stocks are hot right now. This form of medicine based on the particular genes, proteins, and other substances in a person's body.

The 7 Best Biotech Stocks for Personalized Medicine Investors

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented two preclinical poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

ORIC has a few early stage cancer targeting molecules. In December, Pfizer made a small $25mn deal with it for the lead asset.

ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets

ORIC-944 preclinical poster presentation to highlight comprehensive biomarker strategy for ongoing Phase 1 trial in metastatic prostate cancer

ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) --  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 2:00 p.m. ET.

ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Elys Game Technology, Corp.

Gossamer Bio Inc

Kala Pharmaceuticals

Myomo

Soleno Therapeutics

Sitio Royalties Corp

While everyone knows that in order to have a market, there must be bulls and bears, that's not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position.

7 Top Short-Squeeze Candidates to Watch in February

News for Oric Pharmaceuticals Stock (ORIC)